

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/201502 A1

(51) International Patent Classification:

A61K 39/095 (2006.01) *C12N 15/31* (2006.01)
A61P 31/04 (2006.01) *C12N 15/63* (2006.01)
C07K 14/22 (2006.01) *C12N 15/70* (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IN2024/050300

(22) International Filing Date:

22 March 2024 (22.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202321021121 24 March 2023 (24.03.2023) IN

(71) Applicant: **SERUM INSTITUTE OF INDIA PRIVATE LIMITED** [IN/IN]; 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, 411 028 Maharashtra (IN).

(72) Inventors: **PISAL, Sambhaji Shankar**; c/o SERUM INSTITUTE OF INDIA PRIVATE LIMITED, 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **ANNAMRAJU, Dattatreya Sarma**; c/o SERUM INSTITUTE OF INDIA PRIVATE LIMITED, 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN). **DHERE, Rajeev Mhalasakant**; c/o SERUM INSTITUTE OF INDIA PRIVATE LIMITED, 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411 028 (IN).

(74) Agent: **WILSON, Neeti** et al.; Anand & Anand Advocates, B-41, Nizamuddin East, New Delhi 110013 (IN).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2024/201502 A1

(54) Title: MENINGOCOCCAL PROTEIN BASED VACCINE FORMULATIONS AND METHODS FOR MANUFACTURING THEREOF

(57) Abstract: Present invention provides fusion proteins with desired reduction in factor H binding, particularly the present invention provides optimized manufacturing process for fusion proteins and formulations comprising the fusion proteins. Present invention provides an efficient platform process for manufacturing an effective vaccine formulation against *Neisseria meningitidis* that meets multiple criteria including improved immunogenicity, safety, stability, and affordability.